Articles tagged with Brain Tumors
A Northwestern University study found that brain cancer patients with malignant gliomas tend to overestimate their quality of life compared to their caregivers. The research suggests that caregivers play a crucial role in providing a more accurate assessment of the patient's well-being.
A new study identifies a crucial gene in pediatric high-grade glioma, which may lead to the development of more effective drugs. The research found that the PDGFRA gene is unusually active in childhood cancer and is likely to be an important drug target.
Researchers at Thomas Jefferson University found that hypofractionated stereotactic radiotherapy significantly improves survival rates for patients with recurrent brain cancers, while minimizing side effects. The treatment provides longer survival without experiencing common chemotherapy and targeted therapy side effects.
A study led by St. Jude Children's Research Hospital identified a cancer gene unusually active in some childhood brain tumors, providing a new treatment target for high-grade gliomas (HGGs). The research found significant differences between genetic defects in children and adults with HGG.
Researchers found that PDE5 inhibitors increase blood-brain barrier permeability to Herceptin, boosting effectiveness against lung and breast cancer brain metastases. The combination of vardenafil plus Herceptin improved survival by 20% in mouse models.
Researchers have found that parvoviruses can completely regress malignant brain tumors in rats and human gliomas. The viruses target cancer cells without affecting healthy tissue, making them a potential new approach to treating glioblastoma.
Researchers at Ohio State University have developed nanoparticles that can enhance MRI scans and surgical procedures for brain tumor removal. The magnetic and fluorescent nanocomposites can help doctors visualize tumors before surgery, allowing for more precise removal.
A new study links brain tumor growth to reduced expression of over 600 immune system genes, revealing the complexity of the immune response to cancer. The research found that immune function genes were suppressed in almost 70% of genes examined, contradicting previous assumptions.
A study by researchers at the University of Texas M.D. Anderson Cancer Center has identified a potential new therapy for brain tumors by analyzing DNA methylation patterns. The discovery may help identify patients with more favorable outcomes and offer a targeted treatment approach.
Scientists have discovered that residual glioblastoma cells have different properties than those found in the tumor mass, making them more mobile and resistant to treatment. This breakthrough could lead to new therapeutic approaches against this aggressive brain cancer.
Researchers discovered new pyrimidine compounds that target Src tyrosine kinases in medulloblastoma cells, showing reduced cell proliferation and tumor progression. These compounds may offer a more effective treatment option for childhood brain cancer, with potential synergistic effects when combined with chemotherapy.
Researchers have developed a minimally invasive endoscopic procedure that can safely remove large brain tumors from an area at the bottom of the skull, near the sinus cavities. The study found that this approach resulted in complete tumor removal in 96% of patients and could be a game-changer for patients with pituitary macroadenomas.
Research at Johns Hopkins Medicine found that underprivileged African-American, Hispanic, and low-income patients with brain tumors are significantly less likely to be referred to high-volume specialty hospitals. This finding contradicts federal health care agency recommendations for equal access and quality of care.
Glioblastoma cells use miR-451 to sense glucose availability, slowing cell proliferation and increasing migration. High miR-451 levels correlate with shorter survival, suggesting the molecule as a biomarker for predicting patient prognosis.
Recent clinical and scientific advancements in nervous system cancers have improved our understanding of molecular changes and new therapies for patients. The March issue of Archives of Neurology features articles on various topics, including increased melanoma risk among Parkinson's disease patients and new insights into glioma risk.
Researchers at Stanford University School of Medicine found that blocking blood vessel formation prevents brain tumor recurrence in mice. Disrupting the SDF-1/CXCR4 interaction prevented tumor regrowth by abrogating functional tumor vasculature.
Researchers have identified a potential therapeutic target for brain cancer, the A20 protein, which is highly expressed in glioblastoma stem cells. Decreasing levels of A20 in these cells reduces their growth and induces cell death, increasing survival rates in animal models.
A key mechanism that makes certain brain cells become tumorous has been identified by researchers. The tumours occur most often spontaneously but can also be part of inherited disease Neurofibromatosis type 2.
Researchers at Stanford University School of Medicine have found that disrupting the SDF-1/CXCR4 interaction can prevent the recruitment of vasculogenic cells to the tumor site, blocking postirradiation development of functional tumor vasculature and tumor regrowth. This approach may be applicable to treating glioblastoma multiforme.
Researchers at Stanford University have discovered a way to prevent glioblastoma cells from growing back after radiation by blocking their access to oxygen and nutrients. The discovery, using the small molecule AMD3100, has shown promise in preventing tumor recurrence.
Research finds that selective brain damage, particularly in parietal regions, can modulate human spirituality and religious attitudes. The study identified a causative link between specific brain lesions and changes in self-transcendence, a personality trait reflecting spiritual feeling and behavior.
A phase 2 trial of denosumab has shown encouraging results in treating a rare type of brain tumor. The study found that 86% of patients experienced a tumor response, including some with lung lesions, and reported clinical benefits such as reduced pain and improved mobility.
Alexander Ksendzovsky, a third-year medical student, has been awarded the Lucien Rubenstein Award for his groundbreaking research on a potential vaccine to fight malignant brain tumors. The American Brain Tumor Association recognized his outstanding work as part of their annual Research Award Program.
Researchers discovered that gliomas can evade EGFR inhibitors by expressing alternative genes like KLHDC8, which halts tumor growth. This finding provides potential new targets and treatment strategies for brain tumors.
Researchers have identified two genes, C/EPB and Stat3, which are responsible for the most aggressive forms of human brain cancer. These genes work together to transform normal brain cells into highly aggressive cells, making them a major target for new treatments.
Researchers at the University of Central Florida have found a protein, TRPC6, that could hold the key to treating GBM, a type of malignant brain tumor. Knocking down this protein's expression can stop tumor growth and spread.
The new guidelines offer a range of therapeutic options and provide evidence-based recommendations for treating brain metastases. The guidelines aim to improve patient outcomes by identifying best treatment practices and fostering support for ongoing research.
Researchers identify specific DNA segment C19MC containing miRNA genes associated with aggressive CNS-PNET tumors. High expression of these miRNAs stimulates growth and prevents normal neural stem cell development.
A recent study published in the Journal of the National Cancer Institute found no significant link between increased cell phone usage and brain tumor incidence. The research analyzed data from Denmark, Finland, Norway, and Sweden over a 30-year period, concluding that induction periods may be longer than previously thought.
Researchers found that the master gene Math1 is critical to the development of medulloblastoma, a deadly disease that affects children and young adults. Removing or inactivating Math1 may work as a treatment, but its effectiveness depends on the stage of brain development.
Atoh1, a transcription factor critical for fetal development, is necessary for the development of many forms of medulloblastoma. Shutting down Atoh1 in susceptible brain cells prevented medulloblastoma from developing in mice, suggesting it as a potential target for new drug treatments.
Duke University researchers have found a way to increase the effectiveness of radiation therapy against glioma brain tumors by blocking a specific signaling pathway in cancer stem cells. This breakthrough could lead to more effective treatment options for patients with glioblastoma and other brain cancers.
Researchers at Ohio State University have developed a tumor-attacking virus that kills brain-tumor cells and blocks the growth of new tumor blood vessels. The virus, called RAMBO, was tested in animal models and showed promise in treating aggressive brain cancer with a survival rate of 54 days.
A new miniature microscope enables neurosurgeons to visualize brain tumors in real-time, allowing for more precise removal and accurate diagnosis. This technology has the potential to reduce surgery time by up to 40 minutes and improve patient outcomes.
Researchers found that multiple sessions of stereotactic radiosurgery (SRS) result in less brain swelling compared to a single high-dose treatment. This innovative approach offers good tumor control with fewer side effects and less time than conventional therapy.
Long-term brain tumor survivors in childhood experience ongoing cognitive problems, with lower levels of education, employment, and income compared to siblings and other cancer survivors. Medical complications such as radiation and surgery also play a significant role in these impairments.
Researchers at University Hospitals Case Medical Center report promising results from a study treating glioblastoma multiforme with Gamma Knife radiosurgery, increasing patient survival rates by almost four months compared to traditional radiotherapy alone.
Two UCSF teams, one for diabetes and one for brain tumors, have received grants from the California Institute for Regenerative Medicine to advance stem cell-based therapies. The goal is to file new drug applications with the FDA within four years, driving potential therapies toward clinical trials.
The first national and evidence-based guidelines for brain metastases have been released in the US, providing a framework for treating patients with brain tumors. The guidelines cover various therapeutic options, evidence-based decision-making, and demographic factors that influence clinical decisions.
ANG1005 demonstrates disease control in over 70% of patients with progressive gliomas and brain metastases, with significant reductions in tumor size observed. The drug successfully crosses the blood-brain barrier without CNS toxicity or immunogenicity.
The Translational Genomics Research Institute has been awarded $691,930 to develop brain tumor research using in silico simulations. The project will utilize comprehensive genomic data involving 40 brain tumor models and 20 proven types of targeted therapies.
Researchers have found that a standard treatment protocol can improve survival rates nearly two-fold for pediatric patients with choroid plexus tumors. The study suggests that chemotherapy and radiation can be effective in reducing mortality rates, contradicting previous research on surgical resection.
A Johns Hopkins study found that Hispanic children diagnosed with brain tumors receive specialized care at one-third the rate of other children, despite efforts to equalize access. The research highlights persistent gaps in care among certain patients and raises concerns about the future impact on this growing demographic.
Fernandez-Valle's research aims to identify proteins that could deliver cancer-fighting drugs to NF2 tumors, potentially improving lifestyles and extending patients' lives. She has established nationally affiliated clinics in Florida, bringing together physicians with expertise in treating the disease.
Patients with brain tumors treated with WBRT plus SRS experience significant decline in learning and memory function compared to those receiving SRS alone. The study concludes that SRS alone combined with close clinical monitoring is the preferred treatment strategy for patients newly diagnosed with one to three brain metastases.
A new approach to treating malignant brain tumors has been discovered, with chemotherapy alone proven to be just as effective as traditional radiation therapy. The study identified a key gene mutation called IDH1 that predicts a better prognosis for patients, regardless of treatment.
Researchers at Weizmann Institute discovered a new protein partnership between TrkA and CCM2 that leads to pediatric tumor regression. This finding may lead to the development of drugs that induce tumor regression. The study found that TrkA and CCM2 are always expressed together in tumors with high regression rates.
Researchers have discovered a small peptide that stops lung cancer tumors from growing by inhibiting blood vessel formation. The study showed significant reduction in tumor size and fewer blood vessels compared to untreated animals.
Researchers have developed a targeted cancer treatment using nanomaterials that selectively kills brain cancer cells while leaving healthy cells unaffected. The therapy uses titanium dioxide nanoparticles bonded to biological material and targets specific cell surface receptors on cancer cells.
A protein called Huwe1 normally functions to eliminate unnecessary proteins, acting as a tumor suppressor in brain cancer. Deregulation of Huwe1 function is involved in tumor development and may be an important factor in the development of brain cancer.
Researchers found that STAT3 inhibits the growth and self-renewal of glioblastoma stem cells, suggesting a promising target for cancer therapy. The study demonstrates the potential of STAT3 inhibitors to stop tumor formation and offers a new approach to treating this devastating brain cancer.
Patients who received radiotherapy for low-grade glioma brain tumors showed significant cognitive decline compared to those who did not receive treatment. The study found that attentional functioning, executive functioning, and information processing speed were lower in patients given radiotherapy. Deferring treatment or using modern r...
Researchers at the University of Washington developed nanoparticles that cross the blood-brain barrier, illuminating brain tumors and improving MRI and optical imaging. This breakthrough could lead to more precise surgery and earlier cancer detection.
UCLA researchers developed a new way to scan brain tumors and predict which ones will respond to the drug Avastin before treatment. By linking high water movement in tumors to positive drug response, they predicted with 70 percent accuracy which patients' tumors were the least likely to grow six months after therapy.
The Peninsula College of Medicine and Dentistry has received a grant to study the role of brain tumors in deafness and develop non-invasive therapies. The research aims to identify how tumors grow and cause hearing damage, and test drug-based treatments.
Researchers at Cedars-Sinai Medical Center have isolated stem-like cells from benign pituitary tumors and shown they can generate new tumors in laboratory mice. The study supports the cancer stem cell hypothesis, suggesting similar mechanisms may be involved in malignant and benign tumor formation.
Researchers discovered that glioma cells use microglia, the brain's immune cells, to grow and expand rapidly. By manipulating microglial cells' receptors, gliomas can clear the way for further growth.
A network of 31 mutated genes has been identified as the driving force behind glioblastoma growth. Annexin A7, a vital guard gene, is lost in most cases, allowing tumors to flourish. The discovery offers new therapeutic targets and potentially extends patient survival.
A recent study published in JAMA Network has found a network of altered genes that appear to play a crucial role in the development and progression of brain tumors. The researchers identified seven landscape genes that are associated with patient prognosis and survival.
A new medical treatment using bevacizumab has successfully improved hearing and alleviated symptoms in patients with neurofibromatosis type 2 (NF2). The study shrank characteristic tumors, including vestibular schwannomas on the balance and hearing nerves.